Citigroup
BEAM icon

Citigroup’s Beam Therapeutics BEAM Stock Holding History

Citigroup’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.77M Buy
138,866
+72,008
+108% +$2.17M ﹤0.01% 2184
2026
Q1 		$1.59M Buy
66,858
+40,101
+150% +$1.11M ﹤0.01% 2815
2025
Q4 		$742K Sell
26,757
-24,544
-48% -$626K ﹤0.01% 3328
2025
Q3 		$1.25M Sell
51,301
-58,119
-53% -$1.16M ﹤0.01% 3024
2025
Q2 		$1.86M Sell
109,420
-110,776
-50% -$1.93M ﹤0.01% 2708
2025
Q1 		$4.3M Buy
220,196
+65,470
+42% +$1.72M ﹤0.01% 2035
2024
Q4 		$3.84M Buy
154,726
+47,342
+44% +$1.21M ﹤0.01% 2226
2024
Q3 		$2.63M Buy
107,384
+17,049
+19% +$440K ﹤0.01% 2424
2024
Q2 		$2.12M Sell
90,335
-168,851
-65% -$4.15M ﹤0.01% 2306
2024
Q1 		$8.56M Buy
259,186
+71,598
+38% +$2.23M 0.01% 1337
2023
Q4 		$5.11M Sell
187,588
-10,009
-5% -$249K ﹤0.01% 1580
2023
Q3 		$4.75M Buy
197,597
+34,943
+21% +$937K ﹤0.01% 1465
2023
Q2 		$5.19M Sell
162,654
-56,847
-26% -$1.84M ﹤0.01% 1467
2023
Q1 		$6.72M Buy
219,501
+102,451
+88% +$4.04M ﹤0.01% 1339
2022
Q4 		$4.58M Sell
117,050
-18,114
-13% -$811K ﹤0.01% 1515
2022
Q3 		$6.44M Sell
135,164
-19,104
-12% -$1.09M ﹤0.01% 1398
2022
Q2 		$5.97M Buy
154,268
+103,543
+204% +$4.12M ﹤0.01% 1434
2022
Q1 		$2.91M Sell
50,725
-36,578
-42% -$2.4M ﹤0.01% 2049
2021
Q4 		$6.96M Buy
87,303
+46,989
+117% +$4.02M ﹤0.01% 1614
2021
Q3 		$3.51M Sell
40,314
-19,091
-32% -$1.92M ﹤0.01% 2054
2021
Q2 		$7.65M Buy
59,405
+13,440
+29% +$1.07M ﹤0.01% 1600
2021
Q1 		$3.68M Buy
45,965
+33,935
+282% +$3.23M ﹤0.01% 2032
2020
Q4 		$982K Buy
12,030
+9,924
+471% +$488K ﹤0.01% 3557
2020
Q3 		$52K Sell
2,106
-1,852
-47% -$45.9K ﹤0.01% 5571
2020
Q2 		$111K Buy
3,958
+439
+12% +$9.46K ﹤0.01% 5495
2020
Q1 		$63K Buy
+3,519
New +$76.5K ﹤0.01% 5751

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Citigroup's BEAM Position: Q2 2026 in Review

Citigroup increased its Beam Therapeutics (BEAM) stake by 108% in Q2 2026, buying an estimated $2.17M and bringing the position to 138,866 shares worth $4.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2184.

Citigroup first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. The position peaked at $8.56M in Q1 2024. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Citigroup held 138,866 shares of Beam Therapeutics worth $4.77M as of Q2 2026.
  • Citigroup bought 72,008 Beam Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Beam Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #2184 holding.
  • Citigroup first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Citigroup's Beam Therapeutics position peaked at $8.56M in Q1 2024.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.